CoQ10: what the evidence actually says.

What CoQ10 is

Coenzyme Q10, also called ubiquinone in its oxidized form and ubiquinol in its reduced form, is a lipid-soluble molecule the body manufactures endogenously. It sits in the inner mitochondrial membrane and shuttles electrons between complex I or II and complex III of the electron transport chain. Without it, oxidative phosphorylation does not function. ATP production halts.

It is also one of the body's primary lipid-soluble antioxidants, protecting cell membranes and circulating LDL particles from oxidative damage. So CoQ10 sits at the intersection of energy production and oxidative defense, which is why its name appears in cardiology, neurology, endocrinology, and dermatology literature.

Why levels decline

Endogenous CoQ10 synthesis falls progressively with age. By the seventh decade, tissue concentrations in the heart and skeletal muscle have dropped by thirty to sixty percent compared to the third decade. The shared biosynthetic pathway with cholesterol also means that statin therapy, by blocking HMG-CoA reductase, reduces circulating CoQ10. This is established. It is not controversial.

Selected cardiovascular conditions, particularly heart failure with reduced ejection fraction, also show lower myocardial CoQ10 on biopsy compared to controls. Whether that is causal or downstream of the disease is still debated.

The trials that move the needle

The Q-SYMBIO trial, published in JACC Heart Failure in 2014, randomized 420 patients with chronic heart failure to CoQ10 100 milligrams three times daily or placebo over two years. The CoQ10 arm showed a statistically significant reduction in major adverse cardiovascular events, mortality, and hospitalization. This was the cleanest signal in the cardiovascular literature for a supplemental antioxidant in decades.

Smaller trials have also shown improvements in endothelial function, mild improvements in left ventricular ejection fraction in heart failure, and reduction in statin-associated muscle symptoms in selected patients. The migraine prophylaxis literature is suggestive but mixed.

Who actually benefits

Three populations have the strongest case. First, patients with heart failure with reduced ejection fraction, where Q-SYMBIO sits as the foundation. Second, adults on chronic statin therapy who report muscle symptoms; the evidence here is not definitive but the risk-benefit favors a trial. Third, selected men over fifty with clinical pictures suggestive of mitochondrial fatigue, low VO2 max, slow recovery, particularly if they have measurable low circulating CoQ10.

Outside of these populations, the case is weaker. A healthy thirty-year-old eating an unprocessed diet has no clear reason to supplement.

Dose, form, and what to look for

Ubiquinol, the reduced form, has somewhat better oral bioavailability than ubiquinone in adults over forty. Doses in the trial literature range from 100 to 300 milligrams daily, typically split into two doses and taken with a meal containing fat. CoQ10 is lipid-soluble; absorption on an empty stomach is poor.

Look for third-party tested products, USP verified or NSF certified. The supplement industry is poorly regulated. Two products labeled identically can contain very different amounts of active compound.